Gonadorelin: research
A short-acting fertility hormone used in tests and specialist pump therapy.
Also called: GnRH, LHRH, gonadorelin acetate, gonadorelin hydrochloride, Factrel, Lutrepulse.
Reproductive axis peptides · Gonadotropin-releasing hormone receptor agonist · Evidence: Approved drug.
At least 51 studies in separate reviews, 35 in women and 16 in men. More reports are listed; twice-weekly shots alongside testosterone therapy lack a controlled fertility trial.
Studies
- Hypothalamic amenorrhea: 35 studies. meta-analysis, n=1002, Women with hypothalamic amenorrhea. Pulsatile GnRH can induce ovulation in hypothalamic amenorrhea. (source)
- Male fertility: 16 GnRH studies. meta-analysis, Men with hypogonadotropic hypogonadism and azoospermia. Pulsatile GnRH can restore sperm production in diagnosed hormone deficiency. (source)
- GnRH versus gonadotropins. meta-analysis, n=420, Men with congenital hypogonadotropic hypogonadism. Earlier sperm appearance did not establish a higher pregnancy rate. (source)
- Lutrepulse: multicenter fertility study. open-label, n=109, Women with primary or secondary hypothalamic amenorrhea. The historical program studied pump therapy, not occasional TRT injections. (source)
- LutrePulse: posted phase 3 results. rct, n=39, Women with primary amenorrhea and hypogonadotropic hypogonadism. Posted randomized results show an ovulation signal with higher pump doses. (source)
- FHA: 25-year pump cohort. cohort, n=66, Women aged 20–40 with functional hypothalamic amenorrhea. Pump therapy produced high ovulation rates with few multiple pregnancies. (source)
- CHH: pump versus hCG/hMG. cohort, n=202, Men with congenital hypogonadotropic hypogonadism. Pumps were associated with earlier sperm appearance than hCG/hMG. (source)
- CHH: 92-patient comparison. cohort, n=92, Men with isolated hypogonadotropic hypogonadism. The pump group had earlier sperm appearance in a nonrandomized comparison. (source)
- CHH: pump versus cyclical hCG/hMG. open-label, n=28, Azoospermic men with congenital hypogonadotropic hypogonadism. Pumps shortened time to sperm appearance in this small comparison. (source)
- CHH: 36-man prospective study. open-label, n=36, Men with idiopathic hypothalamic hypogonadism. Both regimens produced sperm; gonadotropins caused more breast growth. (source)
- Complete IHH: two-year comparison. open-label, n=16, Men starting with testis volume below 4 mL. This older study found no significant pump advantage. (source)
- Hormone deficiency: 26-man series. cohort, n=26, Men with hypothalamic or pituitary hormone deficiency. Both specialist approaches could induce sperm production. (source)
- Longer follow-up: 42-man series. cohort, n=42, Men with hypothalamic or pituitary hormone deficiency. Repeated specialist treatment courses often worked, but cohorts overlap. (source)
- Combined pituitary deficiency. single-arm, n=40, Men with congenital combined pituitary hormone deficiency. Some patients retained a response despite combined pituitary deficiency. (source)
- Five women with IHH. case-series, n=5, Women with idiopathic hypogonadotropic hypogonadism. Most resumed bleeding; two pregnancies were reported. (source)
- Adolescent HH comparison. open-label, n=35, Boys aged 10–16; historical pediatric evidence. This study concerned puberty, not TRT fertility preservation. (source)
- Infant CHH: seven cases. case-series, n=7, Male infants with congenital hypogonadotropic hypogonadism. This pediatric series does not establish unsupervised adult dosing. (source)
- Down syndrome: seven-man pilot. open-label, n=7, Adult men aged 20–50 with Down syndrome. The cognition signal needs randomized confirmation. (source)
- PCOS: a single pregnancy case. case-report, n=1, 28-year-old woman with PCOS and normal baseline LH. A successful case does not establish a PCOS regimen. (source)
- After steroid use: hormone challenge. cohort, n=26, 13 former androgen users, 8 healthy controls and 5 men with IHH. Hormone-challenge responses after steroid use do not establish a maintenance regimen. (source)
Gonadorelin dosage
Typical reported dose: 200 mcg every 3.5 days (twice a week)
- Pituitary response test: SC: 100 mcg once single diagnostic injection, under the skin. Clinician-published. Studied in: Adults undergoing an organized pituitary test. (source)
- Pituitary response test: IV: 100 mcg once single diagnostic injection, into a vein. Clinician-published. Studied in: Adults undergoing an organized pituitary test. (source)
- LutrePulse: 10 mcg pulses: 10 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
- LutrePulse: 15 mcg pulses: 15 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
- LutrePulse: 20 mcg pulses: 20 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Studied in a trial. Studied in: Women with primary amenorrhea and hypogonadotropic hypogonadism. (source)
- Male CHH: response-guided pump: Start 10 mcg per pulse every 90 minutes every 90 minutes by pump, under the skin. Clinician-published. Studied in: Men with confirmed congenital hypogonadotropic hypogonadism. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Gonadorelin side effects and risks
Reported side effects
- Pump-site skin allergy: 7/20 (35%) in one male pump cohort; not a bolus test rate., moderate (source)
- Pain, swelling or itching: UK bolus label: 0.1% to <1%., mild (source)
- Headache, dizziness or nausea: UK bolus label: 0.01% to <0.1%., mild (source)
- Allergy or airway spasm: UK label classifies hypersensitivity and bronchospasm as rare., serious (source)
- IV-line infection or vein inflammation: Historical IV line complications averaged 7%; includes more than infection., serious (source)
- Multiple pregnancy or ovarian over-response: 12% multiple pregnancy in the 1990 program; 1.6% twins in the 2022 cohort., serious (source)
- Pituitary bleeding in a tumor: unknown, serious. Sudden severe headache or vision loss needs emergency assessment. (source)
Stop and get help if
- Sudden severe headache, vision change, vomiting or collapse: Seek emergency care for possible pituitary bleeding.
- Throat swelling, wheeze or faintness after injection: Seek emergency care for possible severe allergy.
- Fever, spreading redness or chills with a pump or IV line: Get urgent assessment for possible infection.
- Severe pelvic pain, rapid weight gain or breathlessness: Get urgent assessment for ovarian over-response.
Who should avoid it
- pregnant: UK product information says not to administer during pregnancy.
- breastfeeding: UK product information says not to administer while nursing.
- tryingToConceive: Specialist fertility use requires diagnosis and monitoring.
- under18: Pediatric research is not an adult self-use regimen.
- hormoneSensitiveCancer: Precaution: gonadorelin raises sex hormones; breast or prostate cancer requires an oncology plan.
- other: GnRH can trigger bleeding into a pituitary adenoma.
- other: Prior allergy to gonadorelin or its excipients can recur.
- other: Primary gonadal failure or poor pituitary reserve can limit response; diagnose the cause first.
- testedAthlete: Prohibited at all times in male athletes under WADA S2.2.1.
- other: Stop for signs of severe allergy or a serious pump-site infection.
Interactions
- Testosterone and other sex hormones: These can alter LH/FSH response. Intermittent gonadorelin has not been shown to preserve fertility during TRT.
- Glucocorticoids: Can affect pituitary gonadotropin secretion and diagnostic interpretation.
- Prolactin-raising drugs: Dopamine antagonists can blunt the GnRH response through higher prolactin.
- Spironolactone, methyldopa and digoxin: Can alter measured gonadotropins and test interpretation.
- Other GnRH medicines: Other drugs acting on the same axis can suppress or change response; they are not dose substitutes.
- Clomiphene with ovulation induction: A historical hyperstimulation case also used clomiphene; combination monitoring matters.
Product quality risks
- An FDA recall included compounded gonadorelin because of sterility concerns.
- A June 2026 FDA warning identified an unapproved gonadorelin product. A research label does not establish approval.
- No representative assay survey of online gonadorelin vials was found.
How Gonadorelin works
Gonadorelin tells the pituitary to release LH and FSH. These hormones signal the testes or ovaries. A pump copies the body’s repeated pulses; the timing is part of the therapy.
- Pituitary GnRH receptor: Releases LH and FSH when responsive pituitary cells are present.
- LH/FSH signaling: Supports sex hormones, follicle growth and sperm production.
Half-life: About 4 minutes in the UK product information.
Gaps: No controlled trial of twice-weekly gonadorelin preserving sperm or pregnancy rates during TRT was found. The 51-study count is a conservative review-based lower bound, not a complete census. Original U.S. label schedules were not retrieved; UK diagnostic schedules are not labelled as FDA/EMA protocols. Forum commonness describes sampled discussions, not measured population prevalence. No same-route, same-frequency human ceiling was found for intermittent TRT shots; pump doses cannot define it. Community vial stability is unknown; UK diagnostic handling cannot be transferred to a different formulation. Cognition benefit beyond the small Down syndrome pilot remains unknown.
Related to Gonadorelin
- Kisspeptin-10: A short-acting experimental peptide that triggers reproductive hormone release.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
Gonadorelin: the short version
Sources
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- FDA warning letter 729447: unapproved gonadorelin (2026-06-17), FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- FDA CDER alert: compounded-drug recall for lack of sterility assurance (2022-04-26), FDA · 2022
- Gonadorelin 100 micrograms powder for solution for injection, Esteve Pharmaceuticals · 2022
- Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment., Boehm U et al. · Nature reviews. Endocrinology · 2015
- Base de Données Publique des Médicaments, ANSM
- Drugs@FDA: FDA-Approved Drugs, FDA
- Drugs@FDA: FDA-Approved Drugs, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
- PREGNYL- choriogonadotropin alfa kit, Organon
- Product information, Health Canada
- Successful ovulation and pregnancy with pulsatile GnRH pump therapy in a polycystic ovary syndrome (PCOS) patient: a case report., Wang S et al. · Frontiers in endocrinology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.